The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s exhibiting significant promise in clinical trials for managing obesity. Unlike some current weight loss approaches, retatrutide appears to offer a more substantial reduction in body weight and benefit metabolic health, p